{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:41:35Z","timestamp":1759992095656},"reference-count":29,"publisher":"EDP Sciences","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1051\/medsci\/2006222188","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T12:22:29Z","timestamp":1299327749000},"page":"188-191","source":"Crossref","is-referenced-by-count":6,"title":["N\u00e9crolyse \u00e9pidermique : M\u00e9canisme de l\u2019apoptose des k\u00e9ratinocytes"],"prefix":"10.1051","volume":"22","author":[{"given":"Jean-Claude","family":"Roujeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel","family":"G\u00e9lard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2006,2,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Rzany B, Stern RS,et al.Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.Arch Dermatol1993; 129 : 92\u20136.","DOI":"10.1001\/archderm.129.1.92"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Roujeau JC, Kelly JP, Naldi L,et al.Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.N Engl J Med1995; 333 : 1600\u20137.","DOI":"10.1056\/NEJM199512143332404"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Lyell A. Toxic epidermal necrolysis : an eruption resembling scalding of the skin.Br J Dermatol1956; 68 : 355\u201361.","DOI":"10.1111\/j.1365-2133.1956.tb12766.x"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Merot Y, Saurat JH. Clues to pathogenesis of toxic epidermal necrolysis.Int J Dermatol1985; 24 : 165\u20138.","DOI":"10.1111\/j.1365-4362.1985.tb05749.x"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Miyauchi H, Hosokawa H, Akaeda T,et al.T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells.Arch Dermatol1991; 127 : 851\u20135.","DOI":"10.1001\/archderm.127.6.851"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Villada G, Roujeau JC, Clerici T,et al.Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells : an immunopathologic study of five cases.Arch Dermatol1992; 128 : 50\u20133","DOI":"10.1001\/archderm.128.1.50"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Correia O, Delgado L, Ramos JP,et al.Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement.Arch Dermatol1993; 129 : 466\u20138.","DOI":"10.1001\/archderm.129.4.466"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Paul C, Wolkenstein P, Adle H,et al.Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis.Br J Dermatol1996; 134 : 710\u20134.","DOI":"10.1111\/j.1365-2133.1996.tb06976.x"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Paquet P, Nikkels A, Arrese JE,et al.Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis.Arch Dermatol1994; 130 : 605\u20138.","DOI":"10.1001\/archderm.130.5.605"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Viard I, Wehrli P, Bullani R,et al.Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.Science1998; 282 : 490\u20133.","DOI":"10.1126\/science.282.5388.490"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Abe R, Shimizu T, Shibaki A,et al.Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas Ligand.Am J Pathol2003; 162 : 1515\u201320.","DOI":"10.1016\/S0002-9440(10)64284-8"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor alpha, interleukin-6 and their receptors in toxic epidermal necrolysis : a comparison with second-degree burns.Int J Mol Med1998; 1 : 459\u201362.","DOI":"10.3892\/ijmm.1.2.459"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Wolkenstein P, Latarjet J, Roujeau JC,et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.Lancet1998; 352 : 1586\u20139.","DOI":"10.1016\/S0140-6736(98)02197-7"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders.Acta Dermatol Venereol1999; 79 : 288\u201390.","DOI":"10.1080\/000155599750010689"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States.Arch Dermatol2004; 140 : 890\u20132.","DOI":"10.1001\/archderm.140.7.890"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.Arch Dermatol2003; 139 : 33\u20136.","DOI":"10.1001\/archderm.139.1.33"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Brown KM, Silver GM, Halerz M,et al.Toxic epidermal necrolysis : does immunoglobulin make a difference\u00a0?J Burn Care Rehabil2004; 25 : 81\u20138.","DOI":"10.1097\/01.BCR.0000105096.93526.27"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Shortt R, Gomez M, Mittman N,et al.Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil2004; 25 : 246\u201355.","DOI":"10.1097\/01.BCR.0000124746.33279.86"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Berthou C, Michel L, Soulie A,et al.Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense.J Immunol1997; 159 : 5293\u2013300.","DOI":"10.4049\/jimmunol.159.11.5293"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Paquet P, Pierard GE. Keratinocyte injury in toxic epidermal necrolysis : simultaneous but distinct topographic expression of CD95R and calprotectin.Int J Mol Med2002; 10 : 145\u20137.","DOI":"10.3892\/ijmm.10.2.145"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity.Curr Opin Immunol2004; 16 : 732\u20137.","DOI":"10.1016\/j.coi.2004.09.016"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Le Cleach L, Delaire S, Boumsell L,et al.Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors.Clin Exp Immunol2000; 119 : 225\u201330.","DOI":"10.1046\/j.1365-2249.2000.01119.x"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Nassif A, Bensussan A, Dorothee G,et al.Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.J Invest Dermatol2002; 118 : 728\u201333.","DOI":"10.1046\/j.1523-1747.2002.01622.x"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Nassif A, Bensussan A, Boumsell L,et al.Toxic epidermal necrolysis : effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol2004; 114 : 1209\u201315.","DOI":"10.1016\/j.jaci.2004.07.047"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Nassif A, Moslehi H, Le Gouvello S,et al.Evaluation of the potential role of cytokines in toxic epidermal necrolysis.J Invest Dermatol2004; 123 : 850\u20135.","DOI":"10.1111\/j.0022-202X.2004.23439.x"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Shresta S, Pham CTN, Thomas DA,et al.How do cytotoxic lymphocytes kill their targets\u00a0?Curr Opin Immunol1998; 10 : 581\u20137.","DOI":"10.1016\/S0952-7915(98)80227-6"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Azukizawa H, Kosaka H, Sano S,et al.Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes.Eur J Immunol2003; 33 : 1879\u201388.","DOI":"10.1002\/eji.200323630"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Chung WH, Hung SI, Hong HS,et al.A marker for Stevens-Johnson syndrome.Nature2004; 428 : 86.","DOI":"10.1038\/428486a"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Hung SL, Chung WH, Liou LB,et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc Natl Acad Sci USA2005; 102 : 4134\u20139.","DOI":"10.1073\/pnas.0409500102"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2006222188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:21:52Z","timestamp":1685974912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2006222188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":29,"journal-issue":{"issue":"2"},"alternative-id":["medsci2006222p188"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/2006222188","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}